Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of IBI363 in Patients with Advanced First-line Gastric Cancer
Sponsor: Xiangdong Cheng
Summary
This is a phase 1b study designed to evaluate the safety, tolerability and efficacy of IBI363 in combination with oxaliplatin and capecitabine (XELOX) in first-line treatment of unresectable advanced or metastatic gastric and gastroesophageal junction adenocarcinoma.
Official title: Phase Ib Study to Evaluate the Safety, Tolerability and Efficacy of IBI363 in Combination with Oxaliplatin and Capecitabine (XELOX) in First-line Treatment of Unresectable Advanced or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2024-10-15
Completion Date
2026-12-31
Last Updated
2024-11-20
Healthy Volunteers
No
Conditions
Interventions
IBI363
IBI363 Q3W Oxaliplatin 130 mg/m2，IV，Q3W, Capecitabine ,1000mg/ m2，PO，Bid，d1-14，Q3W
Locations (1)
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China